FWONK vs MSGS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. FWONK and MSGS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined FWONK and MSGS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

The Formula One Group owns the commercial rights to Formula 1, which means it does not own the teams and does not build cars. It sells the sport. Revenue comes from three main lines: race promotion fees paid by circuits and their government backers for the right to host a Grand Prix, media rights sold to broadcasters and streamers territory by territory, and sponsorship from global brands that want the paddock's audience. Under the Concorde Agreement, a large share of the resulting profit is paid out to the ten (now eleven) competing teams before anything reaches shareholders, so the reported OIBDA is what survives that split. In July 2025 Liberty completed the purchase of Dorna Sports, the commercial rights holder of MotoGP, giving the group a second racing property with the same basic economic shape. Quint, the hospitality business, left the group with the Liberty Live split-off in December 2025, and MotoGP hospitality revenue is now recognised on a net basis as a result.

Full FWONK guide

Madison Square Garden Sports Corp. owns and operates the New York Knickerbockers of the NBA and the New York Rangers of the NHL, along with two development-league affiliates and a professional sports team performance business. Its revenue comes from ticket sales and premium seating, local media rights fees, sponsorship and signage, food and merchandise at games, and its share of leaguewide national media and licensing money. The company does not own Madison Square Garden itself: the arena sits inside MSG Entertainment, and the Knicks and Rangers pay to play there under long-term arrangements, which is why the reported financials look thinner than the size of the underlying assets suggests. Revenue for the trailing twelve months is roughly ~$1.08 billion against a market capitalization of about ~$9.4 billion, a ratio that only makes sense once you treat the company as an asset holder rather than an operating business.

Full MSGS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• FWONK drivers: Contracted rights with long visibility; The US media reset under Apple.
• MSGS drivers: Franchise scarcity; The proposed Knicks and Rangers separation.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Team payments under the Concorde Agreement scale with the sport's profitability, which caps how much of any revenue increase reaches shareholders. For MSGS, the Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick FWONK if you believe its drivers more; MSGS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the FWONK and MSGS guides.

FWONK. At roughly $26.05 billion of market value on roughly $4.02 billion of trailing revenue, FWONK trades near 6.5 times sales, and adding attributed net debt across Formula 1 and MotoGP puts enterprise value closer to $29 billion. Conventional earnings multiples are not useful here: reported operating income was about $73 million for Formula 1 in the second quarter of 2026 purely because four fewer races landed in the period. Comparing full seasons rather than quarters, and watching Adjusted OIBDA after team payments rather than revenue, is the only way the numbers stay legible.

MSGS. Conventional earnings multiples do not describe this stock: the company runs near breakeven on an accounting basis while holding assets appraised at several times its revenue. The more common framework is a sum-of-the-parts, comparing the market capitalization of about ~$9.4 billion against combined franchise appraisals near ~$13.5 billion and then adjusting for borrowings and for the discount attached to a controlled structure. That gap has narrowed considerably over the past year as the shares roughly doubled off a 52-week low near ~$189, so the spin-off outcome now carries more of the weight than the raw appraisal spread does.

Headline figures (approximate, August 2026): FWONK shows revenue (ttm) ~$4.02 billion, market capitalisation ~$26.05 billion, share price ~$103.90, formula 1 revenue (q2 2026) ~$764 million, down ~38% on four fewer races; MSGS shows share price ~$390, market capitalization ~$9.4 billion, revenue (ttm) ~$1.08 billion, net income (ttm) ~-$22 million (EPS ~-$0.93).

FWONK and MSGS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined FWONK and MSGS exposure against your real portfolio. It is not an investment adviser.